Rapamycin (Sirolimus) Licensed by Pfizer

Catalog No.S1039

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Price Stock Quantity  
USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Rapamycin (Sirolimus) Chemical Structure

Rapamycin (Sirolimus) Chemical Structure
Molecular Weight: 914.18

Validation & Quality Control

Cited by 62 publications:

12 customer reviews :

Quality Control & MSDS

Related Compound Libraries

mTOR Inhibitors with Unique Features

  • Pan mTOR inhibitor

    KU-0063794 mTORC1 and mTORC2, IC50=~10 nM.

  • FDA-approved mTOR Inhibitor

    Temsirolimus (CCI-779, NSC 683864) Approved by FDA for Renal Cell Carcinoma (RCC).

  • Newest mTOR Inhibitor

    XL388 Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

  • Classic mTOR Inhibitor

    BEZ235 (NVP-BEZ235, Dactolisib) Dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM/5 nM/7 nM/75 nM/6 nM, respectively.

Product Information

  • Compare mTOR Inhibitors
    Compare mTOR Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets mTOR [1]
(HEK293 cells)
IC50 ~0.1 nM
In vitro Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HT-29MoTuR5l1d3SxeHnjJGF{e2G7M37uO|ExKG6PM{\uelczKGh?NXLOUXlvTE2VTx?=M4jSSnBwfGWwdHnheIV{KGOjbYD0c5Rp\WOrbj3pcoR2[2WmIHP5eI91d3irY3n0fS=>M2\CelI1QTByOEez
HT-29NV:zNWVCS3m2b4TvfIlkKEG|c3H5NXfpOI8zOTBibl2=MV:3NkBpMnf0SG1UVw>?MkLCVI91\W62aXH0[ZMh\GmpaYTvfIlvNWmwZIXj[YQh[3m2b4TvfIlkcXS7NXPDVllVOjR7MEC4O|M>
HT-29NI[zT4NEgXSxdH;4bYMhSXO|YYm=M{PDWVExKG6PNGKydlY4OiCqNXGwV2tITE2VTx?=NFj1d4JRd3SnboTpZZRmeyB3LX\seY9zd3W{YXPpcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>?MWeyOFkxODh5Mx?=
PC3NVrWRlJWU2mwYYPlJGF{e2G7MV6xNFAhdk1?NWLyU4lQOSCqMVjEUXNQM4D3[nBwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kA9OTBibl2uMUCyNVk4QDZ6Mx?=
PC3NGHsOG1McW6jc3WgRZN{[Xl?MojoNVAxKG6PNHHxfW8yKGh?NWe2WVZKTE2VTx?=M33rWmRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:wMXiyNVk4QDZ6Mx?=
PC3NHu3PG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3rvdVEvPSEQvF2=MXKxJIg>NG[5PHZFVVORNH61VolKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy|IIfpeIghUUN3MDDv[kA9OTBibl2=M4jqO|IyQTd6Nkiz
HEK293MVfGeY5kfGmxbjDBd5NigQ>?NIHxSlMyODBibl2=MVG4JIg>NEG1cXZFVVORNUPYd2ZlUW6qaXLpeJMhXFCDLXnu[JVk\WRiZHXndoFl[XSrb36gc4YhWGSlZESge4l1cCCHQ{WwJI9nKDVyIH7NM1j3OlIyPTN7M{Cx
BT-20M2LQS2tqdmG|ZTDBd5NigQ>?NGPuUHozOCEQvF2=MnTZSG1UVw>?NV;wVW9tTG:nczDuc5QhcW6qaXLpeEBuXE:UQ{Kg[IVx\W6mZX70JJBCc1RiU{S3N{BxcG:|cHjvdplt[XSrb36=NUnjVJFCOjF|NUO1OVE>
U937NYrYVoZySW62aXLhZ5RmemmjbDDBd5NigQ>?NEXERYo2OCEQvF2=NVnFSWZlPDhiaB?=MWjEUXNQNWHXc2lrUW6mdXPld{BidnSrYnHjeIVzcWGuIHHjeIl3cXS7IHHnZYlve3Rid3ns[EB1gXCnIFzl[4lwdmWubHGgdI5mfW2xcHjpcIEhWGirbHHk[YxxcGmjLUGgTnI{OiCrbjDVPVM4KGOnbHzzMV:yNVE1OjFyNh?=
U937MmX6RY51cWKjY4TldolidCCDc4PhfS=>M365NFUxKM7:TR?=M4fk[lQ5KGh?MUfEUXNQMYHEc4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JG1KWCCycn;0[YlvNWSnZnnjbYVvfCCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJGpTOzJvMjDpckBWQTN5IHPlcIx{M{TNdFIyOTR{MUC2
U937MmmyRY51cWKjY4TldolidCCDc4PhfS=>NYfFNGlNPTBizszNNFu3U2I1QCCqMWHEUXNQMVzEc4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JGV{[2incnnjbIliKGOxbHmgTGIyODFiaX6gWVk{PyClZXzsdy=>M1XIRVIyOTR{MUC2
MCF-7MVjBeZRweGijZ4mgRZN{[Xl?M2\LOVMxKG6PMlraOEBpNED0[ZZFVVORNHz0fIVKdmS3Y3XzJIF2fG:yaHHnfS=>MXKyNFAzQDF|NB?=
U87MGNFvKWpZMcW6jc3WgRZN{[Xl?NYLLN|g1OSEQvF2=NH;QXIw3KGh?NGHuR4dFVVORMYrQc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdg>?M3nkU|E6QDR6NEC0
U87MGNGGyfFJMcW6jc3WgRZN{[Xl?M1ixPFEh|ryPNWXwTWRvPiCqNELabWVFVVORNYDaflV6WG:2ZX70cJkhcW6qaXLpeJMhPEWEUEGoWFcxMSCyaH;zdIhwenmuYYTpc44>M2\udlE6QDR6NEC0
U87MGMUXLbY5ie2ViQYPzZZk>NFLyXW8yKM7:TR?=NV\k[GxMPiCqNGDaNotFVVORNH;QfIJFd2W|IH7veEBqdmirYnn0JI1VV1JvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?=M1;LSVE6QDR6NEC0
U87MGNWfxRm0yU2mwYYPlJGF{e2G7NIPyVHkyKM7:TR?=MlniOkBpMkHVSG1UVw>?NGrqUmpFd2W|IH7veEBqdmirYnn0JHAuPEWEUEGoWFM4NzR4KTDwbI9{eGixconsZZRqd25?MlK2NVk5PDh2MES=
COS7 cells expressing EGFP-HDQ74/rhebMnzvRZV1d3CqYXf5JGF{e2G7MoL5NE4zKM7:TR?=M3PBNlI1KGh?NH\pOHZFVVORNETLcXFKdmS3Y3XzJIF2fG:yaHHnfS=>NETCfVIyQDN7MUm0PS=>
COS7 cells expressing EGFP-LC3MX\BeZRweGijZ4mgRZN{[Xl?MYOwMlIh|ryPM{W4bVI1KGh?NEXHS2RFVVORMnqzTY5lfWOnczDheZRweGijZ4m=NF7HeZcyQDN7MUm0PS=>
H4MYHGeY5kfGmxbjDBd5NigQ>?NVXPelF7OC5{IN88US=>NV3ZcI45OjRiaB?=NHHaO4VFVVORNGr1fI9KdmO{ZXHz[ZMhfGinIILheIlwKG:oIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAzKHSxIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAyKGmwIHj1cYFvKEh2IHPlcIx{MnSyNVgxOjR3OES=
HeLaMlrxSpVv[3Srb36gRZN{[Xl?NYjMXW1jOTByIH7NNGjJPXo{PiCqNXTMS5VvTE2VTx?=NY\sZZc1UW6mdXPld{BHWkJiS{KwPVVRNCCWMkC5PGwtKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>?NFnPN5MyPzV4M{O4OS=>
HeLaMUPGeY5kfGmxbjDBd5NigQ>?NV7qOlVmOTByIH7NM3G1TlM3KGh?MXHEUXNQNUHxZW9LUW6mdXPld{BHWkJiV{KxNFFHKG23dHHueE12[mmzdXn0bY5EKGmwdHXyZYN1cW:wNXvEeowyOTd3NkOzPFU>
HeLaM3:4cWZ2dmO2aX;uJGF{e2G7NILVNJkyODBibl2=MV[zOkBpMo\USG1UVw>?MlvrTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;uMo\2NVc2PjN|OEW=
SYFMVHGeY5kfGmxbjDBd5NigQ>?NUHaVG5QOTByIH7NNHrRO2IzPCCqMnvISG1UVw>?NHrt[WhKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44>MXWxO|U3OzN6NR?=
SYFMmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1XCdlExOCCwTR?=MkmzNlQhcA>?M13L[mROW09?M4PseGlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDTXWYh[2WubIO=NFHVU4YyPzV4M{O4OS=>
HEK293TNYrk[otOSW62aY\pdoFtKEG|c3H5M3nYPFEhdk1?MlHVOEBlNVP2PWNDTE2VTx?=MVfJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhWjVid3n0bEBGSzVyIH;mJFAvOSCwTR?=MkHmNVc1QDV3MEG=
HEK293TM1XUNmFvfGm4aYLhcEBCe3OjeR?=NWK4[VBJOSCwTR?=MVW0JIQ>M3HnTWROW09?NHL2ZXdKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiWESge4l1cCCHQ{WwJI9nKDBwMzDuUS=>M1ToTlE4PDh3NUCx
PBMCMYfGeY5kfGmxbjDBd5NigQ>?M1;4VlEhdk1?NFrrN5YyPCCmNH7NdGZFVVORM3mw[HJm\HWlZYOgR2NTPSCmZX7zbZR6Mon5NVc1QDV3MEG=
PBMCNWf4[oJTTnWwY4Tpc44hSXO|YYm=M{iwclEhdk1?NV\NVm9WOTRiZB?=MnL0SG1UVw>?NWXYcodoTG:nczDuc5Qh[W[oZXP0JGNZS1J2IHTlcpNqfHl?M2jVSFE4PDh3NUCx
HEK293 cellsMUHLbY5ie2ViQYPzZZk>M17MS|UxKG6PNEHkPJA1PSCvaX6=NUHBNGxrTE2VTx?=MWnJcohq[mm2czDtWG9TKGurbnHz[UBi[3Srdnn0fUB4cXSqIFnDOVAhd2ZiMD6xJI5ONVfTXpBQOTd|NUC5OVM>
Drosophila melanogaster S2 cells transfected with N-luc and C-lucNUC3PYxoTnWwY4Tpc44hSXO|YYm=NUHlVYl2OTByIH7NM1e1cFQhcA>?MknsSG1UVw>?MUPJcoR2[2W|IHz1Z4ln\XKjc3WgdJJwfGWrbjD0doFvey2|cHzpZ4lv\yCrbjDEdo9{d3CqaXzhJI1mdGGwb3fhd5RmeiCVMjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKE5vbIXjJIFv\CCFLXz1Zy=>MornNVcyOjh{NkK=
Human mixed lymphocyteM{juNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY[1JI5ONG\WZmtFVVORNXfPT2RqUUN3ME2xMlYhdk1wNXzSWVB5OTZzOEW4OlU>
Lewis rat lymph node cellsM{noZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3pOUDPxE1?MWPEUXNQMkH2TWM2OD1{Lk[g{txONUDsNXNZOTZzOEW4OlU>
cells from the thymus of normal BALB/c miceMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWWxNEBvVQ>?MYi3NkBpMYTEUXNQNH;k[oRKdmirYnn0d{BtgW2yaH;wdo9tcW[ncnH0bY9vKCiOQV[pJJdqfGhiSVO1NEBw\iB|IH7NNWfzVIc3OTByMkG5OFg>
MRK-nu-1NX3pWXoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mli4TWM2OD1yLki0OUBxVQ>?NX7rblI2W0GQR1XS
OCUB-MNWHt[2VYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGfFcY5KSzVyPUWuNlQheE1?MXXTRW5ITVJ?
SF539NUHpTWdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjiVZRXUUN3ME2xNU43KHCPNH;QSnJUSU6JRWK=
ES4NVzhPI9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{O1bWlEPTB;MkGuOUBxVQ>?NVrVb2tvW0GQR1XS
RL95-2NI\jbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfTO5ljUUN3ME2xNFcheE1?NVnie2dPW0GQR1XS
LC-2-adMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3rYRmlEPTB;NEKzJJBONF3lZWxUSU6JRWK=
DaudiNF3wcHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPuW2NKSzVyPUSzOEBxVQ>?MlPVV2FPT0WU
NTERA-S-cl-D1Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTR2MzDwUS=>NHP4WGZUSU6JRWK=
OS-RC-2NF3YeoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWfJR|UxRTZ3MjDwUS=>NFy3UJlUSU6JRWK=
VA-ES-BJMl63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3W4PGlEPTB;N{KzJJBOM3u2R3NCVkeHUh?=
GR-STMonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTh2NjDwUS=>M1vLUXNCVkeHUh?=
SW872M2fNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17nZ2lEPTB;OES2JJBOMnPtV2FPT0WU
NOS-1M3vxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXKwOpBRUUN3ME24O|EheE1?MWTTRW5ITVJ?
MC116MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlzjTWM2OD17OEWgdG0>NWrNW|VIW0GQR1XS
NCI-H1355M13xTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoK4TWM2OD1zLkCxJI5ONFnGe5RUSU6JRWK=
RPMI-8226Mn;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXi5NnVDUUN3ME2xMlE6KG6PNEfEPJhUSU6JRWK=
TE-15MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTFwM{[gcm0>MWTTRW5ITVJ?
Ramos-2G6-4C10NIXkfWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1;pRWlEPTB;MT60OkBvVQ>?MkfCV2FPT0WU
KU812NVjjXmtOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4SzS2lEPTB;Mj6wNUBvVQ>?M3vUXXNCVkeHUh?=
EW-1M4fwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3W0W2lEPTB;Mj6xO{BvVQ>?MornV2FPT0WU
KS-1NGHtVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2Hsc2lEPTB;Mj60OUBvVQ>?NFr1b2VUSU6JRWK=
SK-LMS-1NFewfIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHfCblNKSzVyPUKuOFkhdk1?M1LKTHNCVkeHUh?=
TGBC1TKBNH\KU|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTJwNkmgcm0>NWHtfJNHW0GQR1XS
TE-6NWG4U2V5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DHcGlEPTB;Mj63O{BvVQ>?MnPhV2FPT0WU
ETK-1M{T4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmPITWM2OD1{LkiyJI5OMl\YV2FPT0WU
BE-13M3j2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTJwOUmgcm0>M3mxV3NCVkeHUh?=
A3-KAWNHfrbFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3PHS2lEPTB;Mj65PUBvVQ>?NUC3[XdDW0GQR1XS
TE-10NXzMTpJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3PLUGlEPTB;Mz6zJI5OMV;TRW5ITVJ?
DOHH-2NF;yNldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVftfGVvUUN3ME2zMlM2KG6PM1TTWnNCVkeHUh?=
ES6MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTNwNEOgcm0>NGXnc3RUSU6JRWK=
OPM-2NWj6fHZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkHkTWM2OD12LkG1JI5OM{jk[nNCVkeHUh?=
SH-4MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{fCU2lEPTB;ND6zOEBvVQ>?MofOV2FPT0WU
NB13MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nhOmlEPTB;ND6zOkBvVQ>?NWnBeVEyW0GQR1XS
HUTU-80MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH63OnlKSzVyPUSuOFIhdk1?NFjkU3FUSU6JRWK=
CCRF-CEMMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1q4VGlEPTB;ND65OEBvVQ>?M4n2bXNCVkeHUh?=
TGBC24TKBNFLFVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkftTWM2OD13LkWxJI5ONXTqXHJTW0GQR1XS
697NVrQ[YFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFnyeGVKSzVyPU[uNlghdk1?M4f3OXNCVkeHUh?=
J-RT3-T3-5NVP0WJNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkmyTWM2OD14LkS2JI5OMUjTRW5ITVJ?
KALS-1M3Hyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTZwNU[gcm0>MV3TRW5ITVJ?
no-10M{HCd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTdwMkmgcm0>NU\EU3VSW0GQR1XS
SK-NEP-1MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mny0TWM2OD16Lke5JI5OM1\WOHNCVkeHUh?=
L-540Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoO4TWM2OD1zMD60NkBvVQ>?MoHmV2FPT0WU
JiyoyeP-2003MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnfiTWM2OD1zMD65OEBvVQ>?NH\ISmNUSU6JRWK=
HHM{XUVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEiw[WRKSzVyPUGxMlM6KG6PNF\XSolUSU6JRWK=
SRM1zrVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\mTWM2OD1zMT60OUBvVQ>?NGC4doVUSU6JRWK=
QIMR-WILNX3POppMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTFzLki1JI5ONWrC[WhiW0GQR1XS
A4-FukMlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jBVWlEPTB;MUOuNVIhdk1?M16zR3NCVkeHUh?=
CESSMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFHy[2NKSzVyPUGzMlE{KG6PNInCfnRUSU6JRWK=
KE-37MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPmTWM2OD1zNj6wO{BvVQ>?Mnj1V2FPT0WU
SK-UT-1MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWf1Vnk3UUN3ME2xOk45OSCwTR?=MnLhV2FPT0WU
SIG-M5NHjCcmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoPXTWM2OD1zNz6yOUBvVQ>?MnLXV2FPT0WU
HTMorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTF5Lk[gcm0>MoHVV2FPT0WU
DELM2njXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTF5Lkm5JI5ONH[wUXlUSU6JRWK=
SK-PN-DWMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTJyLkKzJI5OM2nzNnNCVkeHUh?=
RPMI-8402M2LNUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYf6Wm5wUUN3ME2yNU44PyCwTR?=MkjYV2FPT0WU
RPMI-6666MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHMfnJzUUN3ME2yOE41OiCwTR?=MYTTRW5ITVJ?
NCI-H720MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTJ3LkSxJI5ONYnIflU4W0GQR1XS
EW-16Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTJ4Lki3JI5ONGf0VVdUSU6JRWK=
BL-70M4\QdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXXkNJdHUUN3ME2yPE4{QCCwTR?=M1TqWHNCVkeHUh?=
SF126NXPVTnI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XjXWlEPTB;M{CuN|ghdk1?M1TTRXNCVkeHUh?=
BC-1NVX2PY1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHXYUopKSzVyPUOxMlI3KG6PMnzVV2FPT0WU
MHH-PREB-1NH3HPZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYjJR|UxRTN{LkS0JI5OMonQV2FPT0WU
A101DNVXLXY5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmThTWM2OD1|Mj62NkBvVQ>?MW\TRW5ITVJ?
NMC-G1MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PSWWlEPTB;M{OuOlchdk1?M3vLXHNCVkeHUh?=
LB1047-RCCNVvqdoNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUDjUodEUUN3ME2zOE43QSCwTR?=Mo\IV2FPT0WU
EM-2NUHxbY5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXBTWM2OD1|OD61N{BvVQ>?MWHTRW5ITVJ?
COLO-684MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1rOfWlEPTB;M{muPEBvVQ>?M3;FWnNCVkeHUh?=
BeckerNEXYXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo[3TWM2OD12MT6wOUBvVQ>?NX31doR5W0GQR1XS
BL-41NXXCTYlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXMRZBGUUN3ME20N{43PiCwTR?=M4X2bnNCVkeHUh?=
MDA-MB-134-VINGHCUVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFP4ZYFKSzVyPUS0MlAzKG6PMVrTRW5ITVJ?
L-363MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWLBe|RDUUN3ME20OE44OyCwTR?=NFLKbHhUSU6JRWK=
ECC4M2rnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7zRmplUUN3ME20OE44QCCwTR?=MoDIV2FPT0WU
A388NIeyU3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPYZ3FEUUN3ME20OE45OiCwTR?=NYLoVVVJW0GQR1XS
HELMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{TiW2lEPTB;NEmuO|khdk1?M{LsWHNCVkeHUh?=
RKOMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnWyTWM2OD13MD6yPUBvVQ>?MmGwV2FPT0WU
KINGS-1NGXyW2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRTVzLkW1JI5OM2nxXXNCVkeHUh?=
EB-3M3\0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nlZmlEPTB;NUKuOlchdk1?NY\qUo1CW0GQR1XS
ARH-77Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NImycIxKSzVyPUWyMlghdk1?MXzTRW5ITVJ?
GCIYM1rWWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXzwXGxlUUN3ME21N{41PiCwTR?=NH3PdWFUSU6JRWK=
NCI-H1304M1zNOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlj2TWM2OD13Nz6yNkBvVQ>?MnO4V2FPT0WU
KARPAS-299NI\nZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX3JR|UxRTZzLkiyJI5OMmTCV2FPT0WU
IA-LMNXHZbXRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MljMTWM2OD14OD6xN{BvVQ>?Mon0V2FPT0WU
GI-1MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzUPZh7UUN3ME23NE4{QSCwTR?=NX3HOFlvW0GQR1XS
TE-11NIr5dG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1fzb2lEPTB;N{euNVchdk1?NXvyZZBVW0GQR1XS
LS-411NMkDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MojoTWM2OD15Nz61O{BvVQ>?MknhV2FPT0WU
no-11NHe3WIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXnvTWI4UUN3ME24N{4zPCCwTR?=M2TwUHNCVkeHUh?=
MV-4-11NFfve|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXiTWM2OD16Mz63N{BvVQ>?MV\TRW5ITVJ?
BV-173M1zJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIfPcXVKSzVyPUizMlk4KG6PMl2wV2FPT0WU
CMKNEXtZ3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmHMTWM2OD16ND6xOkBvVQ>?NVX0fpNTW0GQR1XS
LC4-1MlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTh4LkeyJI5OMWrTRW5ITVJ?
COR-L279MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTh5LkK1JI5ONHvuPHBUSU6JRWK=
NCI-H209NIHMOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHW0cnpKSzVyPUi3MlQyKG6PNV7Te3RrW0GQR1XS
RajiNVnxTIdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTh7LkeyJI5OMWHTRW5ITVJ?
LB996-RCCMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MorITWM2OD17Mz60N{BvVQ>?M4q4b3NCVkeHUh?=
NCI-H526NVv6[I1YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTSfoFHUUN3ME25N{42QSCwTR?=MnL1V2FPT0WU
KGNMmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTl4LkK5JI5OMWHTRW5ITVJ?
MOLT-4NYGxeJRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTl4Lke5JI5ONEi2RWlUSU6JRWK=
PF-382MmqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTl4Lke5JI5OMmfZV2FPT0WU
BC-3MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXvvZWh[UUN3ME25PU4yQCCwTR?=M2HV[nNCVkeHUh?=
KARPAS-422MkPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTFyMj6wPUBvVQ>?MVfTRW5ITVJ?
SBC-1MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX7kRox[UUN3ME2xNFcvPzVibl2=MXjTRW5ITVJ?
LC-1FNXHkb2VGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVz1VJNjUUN3ME2xNFgvODVibl2=MkL3V2FPT0WU
GB-1MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmH0TWM2OD1zMEmuNFIhdk1?M4DZPXNCVkeHUh?=
SNB75MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnHTWM2OD1zMUmuOlkhdk1?MVjTRW5ITVJ?
BB65-RCCM2j3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NILsNHhKSzVyPUGxPU46OyCwTR?=MYfTRW5ITVJ?
NCI-N87MnfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFLQV5dKSzVyPUGyNU46QCCwTR?=M{PwenNCVkeHUh?=
IST-MEL1MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUHpdYdSUUN3ME2xNlIvOzhibl2=MkD6V2FPT0WU
HOP-62NIDhWmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn3YTWM2OD1zMk[uPFkhdk1?MYrTRW5ITVJ?
ACNNH\qeVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17RcmlEPTB;MUS2Mlc2KG6PM4q2b3NCVkeHUh?=
DMS-114NWjNXFhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXQVpZKSzVyPUG1NE43PyCwTR?=NGjsWFhUSU6JRWK=
MLMANGnyVWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3PnbGlEPTB;MUW5Mlg5KG6PM1\1ZnNCVkeHUh?=
HT-144M4nOc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVHFeXN4UUN3ME2xOlUvPDNibl2=NFLsWXlUSU6JRWK=
C2BBe1NV6zXlF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1LJeWlEPTB;MU[3Mlc3KG6PM{DYcXNCVkeHUh?=
L-428MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmfyTWM2OD1zN{euO{BvVQ>?Mm\sV2FPT0WU
DU-4475MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWfvemZ4UUN3ME2xPFcvPjhibl2=NUKxfVR3W0GQR1XS
CP67-MELM3e5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLEfGhKSzVyPUG5PU4{QCCwTR?=M4rWTnNCVkeHUh?=
MEG-01MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXG0Wo53UUN3ME2yNFEvQTZibl2=MV7TRW5ITVJ?
IST-SL2NV7reYJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIPI[nNKSzVyPUKwPE43OyCwTR?=MWXTRW5ITVJ?
ES8NIPTSG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XIV2lEPTB;MkK1Mlk1KG6PM4f4cXNCVkeHUh?=
COLO-800NWq4RW9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;JTWM2OD1{M{WuNlghdk1?Mo\HV2FPT0WU
MFH-inoNWDXOJFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2nJOWlEPTB;MkO1Mlg1KG6PM170T3NCVkeHUh?=
OVCAR-4M3vTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTOd|RKSzVyPUKzO{4zPCCwTR?=NYKzOXV1W0GQR1XS
PSN1NYPycJM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{PMe2lEPTB;MkSyMlcyKG6PM{Htc3NCVkeHUh?=
EW-12M322eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PLcmlEPTB;MkSzMlEhdk1?NGq4TnJUSU6JRWK=
HCC1599NYDuemV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTJ4MT60O{BvVQ>?NWj2e4hrW0GQR1XS
SJSA-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHsTWM2OD1{N{GuOFYhdk1?MnnqV2FPT0WU
ST486MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnaTWM2OD1{OU[uNVQhdk1?MXXTRW5ITVJ?
NOMO-1NYLkW3V5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUj4epR5UUN3ME2zNFAvOjFibl2=MWTTRW5ITVJ?
MN-60MoDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\MTWM2OD1|MEWuN|Ihdk1?MlfCV2FPT0WU
HCC1187NIfYVnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTNyNz6yOUBvVQ>?MYTTRW5ITVJ?
SW982MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTNzND63OUBvVQ>?MlmyV2FPT0WU
LB647-SCLCM{exfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\mPGlEPTB;M{K4MlcyKG6PNFn0cm9USU6JRWK=
HC-1M1LWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{\4eGlEPTB;M{O1MlUhdk1?NEHrXFJUSU6JRWK=
EHEBMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXDXm5KSzVyPUOzO{42OiCwTR?=NYC1cplCW0GQR1XS
TURM4\5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF7ONWxKSzVyPUO2N{46PSCwTR?=M4fFe3NCVkeHUh?=
LU-139NYTOPZN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIX0[lFKSzVyPUO3PE4xOiCwTR?=NIHZeVlUSU6JRWK=
NB1NW\MVIJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIm4PGhKSzVyPUO4OE41PSCwTR?=MkD5V2FPT0WU
BB30-HNCNVLFcZE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnn3TWM2OD1|OEiuN|Ihdk1?Ml\pV2FPT0WU
HAL-01MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVX5cop6UUN3ME2zPFkvOjZibl2=MYXTRW5ITVJ?
K5MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTITWM2OD12MUGuN|chdk1?NYnXPYw5W0GQR1XS
MZ2-MELNFrCXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\uc4Z1UUN3ME20NVMvPjRibl2=NYrhdINkW0GQR1XS
RXF393Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjrSm5KSzVyPUSxOk41PSCwTR?=M4jxPXNCVkeHUh?=
NCI-H1648NUPKfpk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4q3WWlEPTB;NEG3MlU{KG6PNGr3[5lUSU6JRWK=
TE-12NI[yNGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTR|ND6yOkBvVQ>?NFjycVdUSU6JRWK=
EoL-1-MmP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTR|Nz65PEBvVQ>?MXfTRW5ITVJ?
JARM4jNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnHmTWM2OD12M{iuOlIhdk1?NHvtRYxUSU6JRWK=
DSH1M3K5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTR3OD65NUBvVQ>?M2jqfHNCVkeHUh?=
NCI-H187MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkXKTWM2OD12NkKuPFEhdk1?MonHV2FPT0WU
HCE-4MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MormTWM2OD12N{euOlYhdk1?M3nk[3NCVkeHUh?=
8-MG-BAM330e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoruTWM2OD13OEGuOVIhdk1?MVTTRW5ITVJ?
KLEMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWPhepd[UUN3ME21PFUvOiCwTR?=NEG5dFlUSU6JRWK=
KNS-42MmfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW[4VWs3UUN3ME21PFYvQDFibl2=MV;TRW5ITVJ?
MSTO-211HMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;SU2lEPTB;NkC5Mlc1KG6PNFTGeW9USU6JRWK=
GDM-1NVi1eXdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk[3TWM2OD14MUSuNFkhdk1?Mm\jV2FPT0WU
TE-1NEPtOYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2CxNGlEPTB;NkS2MlEzKG6PNGO4RoVUSU6JRWK=
BT-474MoXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\PTWM2OD14NEeuNFYhdk1?MWXTRW5ITVJ?
KARPAS-45MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXr4WFZtUUN3ME22OFcvPiCwTR?=NID2U2lUSU6JRWK=
MOLT-16NWnHRllzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTZ2Nz65N{BvVQ>?MUnTRW5ITVJ?
KURAMOCHINETUSotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIS4bYVKSzVyPU[1O{42OSCwTR?=MUXTRW5ITVJ?
K-562Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2O3cmlEPTB;Nk[5MlUyKG6PMVLTRW5ITVJ?
EKVXMmHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXiOJlKSzVyPU[3Nk44OSCwTR?=MW\TRW5ITVJ?
GAKNV7Tc4tnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4jiSmlEPTB;Nke1MlMhdk1?M{nwTXNCVkeHUh?=
NCI-SNU-5MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXa[5pKSzVyPU[5NE4xOSCwTR?=M4nqUHNCVkeHUh?=
NCI-H2126M1PNXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUPJR|UxRTd{Nj64O{BvVQ>?NUG4TGxXW0GQR1XS
CTV-1M{nqTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1zpS2lEPTB;N{S0Mlkhdk1?NF7XN2NUSU6JRWK=
SW962M2PJdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlG0TWM2OD15NEiuOFQhdk1?NF3lPXNUSU6JRWK=
MONO-MAC-6MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PiVGlEPTB;N{W2Mlk{KG6PNU\BXmt[W0GQR1XS
NCI-H748MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PUO2lEPTB;N{W4Mlk6KG6PNF\PWJFUSU6JRWK=
NCI-H524NXHaSnBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NInKNpVKSzVyPUe4NE44OyCwTR?=M4LNVXNCVkeHUh?=
LS-123NUXhOZRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrrRlE3UUN3ME23PVUvPjlibl2=M3npPHNCVkeHUh?=
NB7NHrOUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTvXpBNUUN3ME24NVQvOTRibl2=MmH3V2FPT0WU
LS-1034MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M13DWWlEPTB;OEK4Mlk5KG6PNH\iVlFUSU6JRWK=
TE-5MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUHacop1UUN3ME24PFMvPTZibl2=MX\TRW5ITVJ?
A704NYjVXGdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV:xWYxuUUN3ME24PVkvOTVibl2=NEPTZVlUSU6JRWK=
TK10MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYGycnJkUUN3ME25NVYvODNibl2=NIr6Z|lUSU6JRWK=
NCI-H345NVzRUIVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELPbW5KSzVyPUm0N{4zOiCwTR?=NXzLUlJYW0GQR1XS
CGTH-W-1NWjlT482T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1TtVGlEPTB;OUS4MlE{KG6PM{O0WHNCVkeHUh?=
NCI-H510ANUHvTodkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1W2N2lEPTB;OUi1MlEzKG6PNXHy[FA6W0GQR1XS
NCI-H1963MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYnJR|UxRTFwMEOyPVIh|ryPNHrIfHNUSU6JRWK=
SCC-3MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkjGTWM2OD1zLkCzOFE1KM7:TR?=M2PlN3NCVkeHUh?=
EW-11NGXkb4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4P0XGlEPTB;MT6wPFc1OyEQvF2=NHrZW2tUSU6JRWK=
CPC-NNWXMUnlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjrTmVDUUN3ME2xMlA5QCEQvF2=MVfTRW5ITVJ?
NCI-H1417MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVLS[JI2UUN3ME2xMlEzOjZizszNNWrKPYlIW0GQR1XS
DG-75MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTFwMU[yPFUh|ryPM2Pke3NCVkeHUh?=
HD-MY-ZNGPLcZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTFwMU[0NVYh|ryPM3npdnNCVkeHUh?=
ATN-1NYPXdXlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTFwMk[yNFkh|ryPMk\1V2FPT0WU
KM-H2MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHHdnJKSzVyPUGuNlY1ODhizszNNF7tOnlUSU6JRWK=
NCI-H2081NHrSSJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTFwMk[2N|ch|ryPNYLlcZY5W0GQR1XS
HL-60NGDCRW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTFwMk[5OVkh|ryPNHn3VmxUSU6JRWK=
DBNFThXGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTFwMkeyOFIh|ryPNFrwRYxUSU6JRWK=
NCI-H1522MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYnJR|UxRTFwMki4PFch|ryPNWfTbo4{W0GQR1XS
AM-38NEn4PY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIXK[2xKSzVyPUGuN|A4OiEQvF2=NXO5eplKW0GQR1XS
NCI-H446NFS3fGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoHmTWM2OD1zLkOyNVIyKM7:TR?=NI\EUYlUSU6JRWK=
SU-DHL-1MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXLPWpSUUN3ME2xMlMzQDBzIN88US=>MUXTRW5ITVJ?
NH-12MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWjBTlMzUUN3ME2xMlM3Ozd2IN88US=>MY\TRW5ITVJ?
DMS-79M2Hsemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn:1TWM2OD1zLkO2PFY3KM7:TR?=NFLFcZNUSU6JRWK=
NCI-H716MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2LLTWlEPTB;MT6zPFk5PiEQvF2=M2ThZXNCVkeHUh?=
ML-2NEX2eItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPBUYpKSzVyPUGuOFE2OjlizszNNEG1R2hUSU6JRWK=
NB10NHLETnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH3KemlKSzVyPUGuOFY3OzJizszNMWHTRW5ITVJ?
ONS-76NIPqfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTFwNUO1Olkh|ryPMn\RV2FPT0WU
LOUCYMlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTFwNUS2OVch|ryPMmTDV2FPT0WU
SCLC-21HMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTFwNUi1PFIh|ryPM{S1THNCVkeHUh?=
TGWM1\lTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXL6VpBsUUN3ME2xMlY{QTd3IN88US=>MV\TRW5ITVJ?
LXF-289NFu5XVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7jRZJpUUN3ME2xMlc{OjZ6IN88US=>M2TlTnNCVkeHUh?=
BB49-HNCNUPs[pd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn3NTWM2OD1zLkezOVg3KM7:TR?=NVW3[nFEW0GQR1XS
NCI-H747NVXLWGtmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTrTWM2OD1zLke1N|Q3KM7:TR?=M3q2TnNCVkeHUh?=
LU-165M2DLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jpfWlEPTB;MT64OFk5PiEQvF2=NXK0S5R6W0GQR1XS
OMC-1M4nhWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTFwOUWwOlYh|ryPM2mxPHNCVkeHUh?=
RCC10RGBNITWPZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\jR5VKSzVyPUGuPVU5OTdizszNMnvyV2FPT0WU
SW684M{\WbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHWwOJdKSzVyPUGuPVYxQTlizszNNVHoenhkW0GQR1XS
TE-8NVzWUVl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3[xPWlEPTB;Mj6wOVU2QSEQvF2=M4e4cnNCVkeHUh?=
SK-N-DZMnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4nJVWlEPTB;Mj6xN|I4PCEQvF2=NHj1PYxUSU6JRWK=
EVSA-TM2DZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV7Yfo5kUUN3ME2yMlE4OzF3IN88US=>M3jsfnNCVkeHUh?=
KASUMI-1M1\Ce2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTnTWM2OD1{LkG4PFE2KM7:TR?=NUjLUnJVW0GQR1XS
NKM-1NFW2VWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\sSWlEPTB;Mj6yOVQ4OiEQvF2=M3nRS3NCVkeHUh?=
CAL-148MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUP4OJZQUUN3ME2yMlM{PjF2IN88US=>MWjTRW5ITVJ?
NCI-H64NXjBfm1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUi3RphtUUN3ME2yMlM1OjN{IN88US=>NYjGb|BwW0GQR1XS
KNS-81-FDNHf4eHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLuVWdlUUN3ME2yMlM3PjJizszNM3\ldHNCVkeHUh?=
KM12NHe0e|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV2yN5RLUUN3ME2yMlQxQDN7IN88US=>NXLUV|IzW0GQR1XS
SW954M4L6U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYnFbHdmUUN3ME2yMlQ4Pzd7IN88US=>MlXlV2FPT0WU
NCI-H1395MlfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmeyTWM2OD1{LkWyOlQ2KM7:TR?=MVvTRW5ITVJ?
DJM-1MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoqwTWM2OD1{Lk[wOlMh|ryPM2DlPXNCVkeHUh?=
COLO-668Mm\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPGUIlKSzVyPUKuPFI3QTVizszNNF;ue|hUSU6JRWK=
NCI-H1436NUjI[HppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2i3VWlEPTB;Mj64OVYyPSEQvF2=M2na[XNCVkeHUh?=
LB2241-RCCMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;VXGlEPTB;Mj64Olg{QSEQvF2=NGPNVGlUSU6JRWK=
GT3TKBMl7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4HKN2lEPTB;Mj64PVA2PSEQvF2=Mn25V2FPT0WU
COLO-824NELNVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH22dm1KSzVyPUKuPFk4PjhizszNNGLETWxUSU6JRWK=
ES1NI[xfJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2L0bWlEPTB;Mj64PVg4QSEQvF2=M3iySXNCVkeHUh?=
LB771-HNCMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{D1bmlEPTB;Mj65NFk1PiEQvF2=NVy0e5NsW0GQR1XS
GI-ME-NMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3jNGVGUUN3ME2zMlAxQTB2IN88US=>MWXTRW5ITVJ?
NALM-6M2PTN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTNwMEC5N|Mh|ryPMne5V2FPT0WU
LU-134-AMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MknWTWM2OD1|LkC1OFI2KM7:TR?=MULTRW5ITVJ?
DMS-153MmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXL3NW1TUUN3ME2zMlA2QDJ2IN88US=>MYLTRW5ITVJ?
MZ1-PCM2TTNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTNwMEmwO|gh|ryPNELpTFRUSU6JRWK=
NCI-H1155MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnu2TWM2OD1|LkGxOlEh|ryPNYrFNYhlW0GQR1XS
CAS-1MoSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTNwMUO3NFch|ryPNHLBepRUSU6JRWK=
D-502MGNYjGeoRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTNwMUSzPUDPxE1?M4DS[3NCVkeHUh?=
NCI-H2141MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml7BTWM2OD1|LkG3OFUzKM7:TR?=MmfnV2FPT0WU
NB6MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHnSZJKSzVyPUOuNVgzPTlizszNMmjhV2FPT0WU
NCCITMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTNwMkG4NFkh|ryPNFr4eppUSU6JRWK=
NB69Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTNwM{G4PVEh|ryPNXX3bItXW0GQR1XS
JVM-2NXS0eppNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFfkb2pKSzVyPUOuN|Y1OzNizszNMnLlV2FPT0WU
K052NX;HcIpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MknpTWM2OD1|LkO3PVY5KM7:TR?=NHTtZ|JUSU6JRWK=
HCC2157NFu4SnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTNwNUOyNlgh|ryPNGX4ZlJUSU6JRWK=
KMOE-2NXW3ZmRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTNwNUSyOFIh|ryPNWTrZY1bW0GQR1XS
SF268M{n0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mmm2TWM2OD1|LkexOVU1KM7:TR?=M3eyS3NCVkeHUh?=
CHP-126NF3uVFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF65NJZKSzVyPUOuO|Y1PThizszNMXLTRW5ITVJ?
CP66-MELMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkeyTWM2OD1|Lke5NFk1KM7:TR?=NWjoW41yW0GQR1XS
NCI-H69M3nLUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fXR2lEPTB;ND6wNVk{PiEQvF2=M1n4V3NCVkeHUh?=
A253MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTRwMEKxNFEh|ryPNXzxfYdvW0GQR1XS
NB14NHnmRnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXrhWlF{UUN3ME20MlExPDd7IN88US=>MWHTRW5ITVJ?
NCI-H1694MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkD5TWM2OD12LkGzNVEzKM7:TR?=MlvEV2FPT0WU
NCI-H2196MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWDXPZdSUUN3ME20MlE4OTZ7IN88US=>Mmf3V2FPT0WU
TE-9M3;H[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XHUmlEPTB;ND6xO|U5OiEQvF2=MkTiV2FPT0WU
D-283MEDMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUC1SGJSUUN3ME20MlE5QDRizszNM4T2e3NCVkeHUh?=
OCI-AML2NWfNfYx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHm5fHJKSzVyPUSuNVk1QDlizszNM3THV3NCVkeHUh?=
D-263MGMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELxS4xKSzVyPUSuNlI6PjFizszNNFfZSldUSU6JRWK=
MPP-89MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPOWmRKSzVyPUSuNlc{ODRizszNMoXOV2FPT0WU
LAMA-84M1XnRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\sXJY5UUN3ME20MlMxPDJzIN88US=>NIru[JNUSU6JRWK=
LB373-MEL-DNY\neWt5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NILsNmFKSzVyPUSuN|Y4QDlizszNMXXTRW5ITVJ?
UACC-257NWjJVINbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHT0PIJKSzVyPUSuN|k2OzRizszNM3zabHNCVkeHUh?=
MC-CARNFniT|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{PXUGlEPTB;ND60N|k6KM7:TR?=NHLxXYFUSU6JRWK=
COLO-320-HSRMkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWmx[HRyUUN3ME20MlQ1PDJ5IN88US=>M1X4[nNCVkeHUh?=
P30-OHKNFX1OlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{C2eWlEPTB;ND62OlU5OSEQvF2=NVT0PWZUW0GQR1XS
UACC-812NFXqPGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTRwNkmxOlEh|ryPNXLuSJB{W0GQR1XS
CTB-1NWW1OVI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFv4SGhKSzVyPUSuO|E2PTVizszNNH[x[4hUSU6JRWK=
ALL-POMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYS4XG1{UUN3ME20Mlg1ODd5IN88US=>M3nPRXNCVkeHUh?=
SK-MEL-2MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTRwOE[5OVUh|ryPNIDWV4VUSU6JRWK=
TC-YIKNH7oTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mmj2TWM2OD12Lkm3PVQzKM7:TR?=NXvVb|BTW0GQR1XS
NCI-H1882MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGTPeHNKSzVyPUWuNFIxODFizszNNEPQd25USU6JRWK=
MHH-CALL-2NHTKUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTVwMEWwOFIh|ryPM4PXeXNCVkeHUh?=
U-87-MGMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTVwMEm0OlYh|ryPMXXTRW5ITVJ?
NCI-H1092M2XJe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vQbmlEPTB;NT6yOlU2PSEQvF2=MknZV2FPT0WU
TE-441-TNYfMc2NmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPJTWM2OD13LkK3PFIh|ryPNXLsVYVEW0GQR1XS
SK-MEL-1M4LkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGeye5lKSzVyPUWuNlkxPDRizszNNH7xPW1USU6JRWK=
EW-22NH7HNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPoe5pKSzVyPUWuNlk1PjZizszNM1XJdnNCVkeHUh?=
MZ7-melMmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGTKTJpKSzVyPUWuOFA3QTFizszNM1P1SnNCVkeHUh?=
LP-1MkL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHETWM2OD13LkSxNlkyKM7:TR?=NGr4OlFUSU6JRWK=
NCI-SNU-16NWTSUJdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1PafWlEPTB;NT62OFA4PCEQvF2=M13vfXNCVkeHUh?=
LU-65M2PU[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17TRmlEPTB;NT63OlM4OyEQvF2=M4XjWXNCVkeHUh?=
CW-2Mlz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkewTWM2OD13Lki1PVU6KM7:TR?=MXnTRW5ITVJ?
WSU-NHLNILGZ3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnjGTWM2OD13Lkm1NVc1KM7:TR?=NGrOb4dUSU6JRWK=
IST-MES1NHnjdFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NI\lZmVKSzVyPUWuPVU1PDNizszNNWTGVnBbW0GQR1XS
U-266NGjod|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3L4TGlEPTB;NT65PFIxOiEQvF2=MXrTRW5ITVJ?
TALL-1MlzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEmxWVBKSzVyPU[uNVQ3QDhizszNMoPuV2FPT0WU
Calu-6NUPJ[2o1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFP6[3BKSzVyPU[uNVU{OTZizszNMmjDV2FPT0WU
MMAC-SFMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXnyWZZ7UUN3ME22MlE5PTV4IN88US=>MYfTRW5ITVJ?
NCI-H82NHq5dXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVLpZVRDUUN3ME22MlIxPDh7IN88US=>NGf0ZVZUSU6JRWK=
RS4-11NEPQfG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1O2[mlEPTB;Nj6yOVg6PyEQvF2=Mn:4V2FPT0WU
SNU-C2BNUK2PWVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlniTWM2OD14LkSwPVY6KM7:TR?=MnrpV2FPT0WU
BOKUNF3U[HdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4TXNWlEPTB;Nj60O|U6PyEQvF2=NEL5bm5USU6JRWK=
C8166NX3qRoFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVHLeYRzUUN3ME22MlU2QTF{IN88US=>NFrPTWlUSU6JRWK=
D-247MGMnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnn6TWM2OD15LkC0N|Q4KM7:TR?=MYrTRW5ITVJ?
EW-18M4TIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTdwMEeyPVIh|ryPM37ZVnNCVkeHUh?=
KG-1NUHMVVJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWnxSo1lUUN3ME23MlYzPzN6IN88US=>MorkV2FPT0WU
REHNXLQS2FNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjMXpVKSzVyPUeuOlgyODlizszNMmfQV2FPT0WU
U-698-MMkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnHKTWM2OD15Lki0N|E2KM7:TR?=NYTiWY9xW0GQR1XS
KP-N-RT-BM-1NV70N5BlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTdwOUOwNlkh|ryPM1rMfXNCVkeHUh?=
MS-1NGLXbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3S2XWlEPTB;Nz65OlA1OSEQvF2=NH\mTIxUSU6JRWK=
SNU-C1NIjwT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlXkTWM2OD15Lkm4NVkzKM7:TR?=NUPqVJFlW0GQR1XS
SK-MM-2NEP1NIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PNXmlEPTB;OD6yOlA3PSEQvF2=NF34fllUSU6JRWK=
LAN-6M{HHV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\hSmN1UUN3ME24MlMxODBzIN88US=>MYTTRW5ITVJ?
NEC8MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRThwM{C2PVEh|ryPNFPEVFVUSU6JRWK=
NCI-H1770NULybXJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4XrdWlEPTB;OD6zPFAxOiEQvF2=MmL2V2FPT0WU
D-336MGNXLxRo9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2XxNWlEPTB;OD60NFEyPiEQvF2=NF3Je5BUSU6JRWK=
COLO-829NVHL[GFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHzN[YRKSzVyPUiuOFg5PzlizszNMXrTRW5ITVJ?
LS-513NH\mR|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PRXWlEPTB;OD61PVU6QSEQvF2=MU\TRW5ITVJ?
YTMoTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkfiTWM2OD16Lk[yOFI4KM7:TR?=NGLpVmRUSU6JRWK=
EW-24MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmrmTWM2OD16Lke2OVQh|ryPMWXTRW5ITVJ?
IST-SL1MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRThwOE[1OFMh|ryPM{fkV3NCVkeHUh?=
CA46MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF3kSZRKSzVyPUiuPVUxQThizszNNFzWNZJUSU6JRWK=
NCI-H1838M3LvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRThwOUi2NFIh|ryPMXTTRW5ITVJ?
NCI-H719NYq3d3pVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLYbHVKSzVyPUmuNlUzPzlizszNNEjEPINUSU6JRWK=
HCE-TMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{HGeGlEPTB;OT6zNFg2OSEQvF2=NILWWYVUSU6JRWK=
A498NGrjO4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoSyTWM2OD17LkO2NVI1KM7:TR?=NV74RZo3W0GQR1XS
LB831-BLCMoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;uTWM2OD17Lke2OVIyKM7:TR?=MUfTRW5ITVJ?
SKM-1MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUPtVW9EUUN3ME25Mlg2QTZ|IN88US=>NWj4V5hbW0GQR1XS
THP-1NUHaVlNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml;LTWM2OD17Lkm2PVE5KM7:TR?=NXHtO5NIW0GQR1XS
SHP-77M3PyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVPKdY1VUUN3ME2xNE41ODdizszNNFHzfGhUSU6JRWK=
EW-3NXnnVGtMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3IfJlKSzVyPUGwMlYzQDlizszNNHPzeFBUSU6JRWK=
KY821NUDKb5Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M361dmlEPTB;MUCuO|Y{KM7:TR?=NWO5S202W0GQR1XS
NCI-SNU-1NGPjbnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEjaW3hKSzVyPUGxMlAzOTdizszNMoq1V2FPT0WU
HCC2218NE[xOmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlvBTWM2OD1zMT6zPVg3KM7:TR?=NUDPXlgzW0GQR1XS
IM-9M4XPVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LG[GlEPTB;MUGuOVExPiEQvF2=MonvV2FPT0WU
NCI-H889NH3aT4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTFzLkWzNVMh|ryPNHu3WIpUSU6JRWK=
HDLM-2NILtTZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XxbmlEPTB;MUKuOFE2QSEQvF2=Mm\3V2FPT0WU
LB2518-MELNF[yRmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnWTWM2OD1zMj62PFE2KM7:TR?=MkLLV2FPT0WU
NCI-H23NVvmSpdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUfsSmlJUUN3ME2xN{4zPDJ3IN88US=>M2KxeHNCVkeHUh?=
NB17MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTF|LkS1O|kh|ryPNGTJWG1USU6JRWK=
NCI-H322MNE[xd2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4PlPWlEPTB;MUSuOFA3QCEQvF2=NILKNmpUSU6JRWK=
SUP-T1MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTF2LkSxN{DPxE1?NVjxPW42W0GQR1XS
ES3NIDRW49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fCTmlEPTB;MUWuNFcxOyEQvF2=M{TRUnNCVkeHUh?=
ES5NIDxNo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTF3LkC3PFch|ryPNWe0[oNDW0GQR1XS
NCI-H1650MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTF3LkS5O|kh|ryPM3XMeXNCVkeHUh?=
NCI-H226M2njUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFzQcJJKSzVyPUG1Mlg4PjhizszNMojwV2FPT0WU
COR-L88NFjSWXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXfJR|UxRTF4LkOxOEDPxE1?NXL6[lNpW0GQR1XS
SCC-15NUm3OZZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYriUWliUUN3ME2xOk4{QDZ7IN88US=>Mkm3V2FPT0WU
GOTOMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2m2UWlEPTB;MU[uOFc6OyEQvF2=Moe3V2FPT0WU
SIMANYLzNFVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrQTWM2OD1zNj60PFAzKM7:TR?=NIjobZBUSU6JRWK=
NCI-H1299MlfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TtNGlEPTB;MUeuNVU6OSEQvF2=MYHTRW5ITVJ?
NCI-H1581M122Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2Loe2lEPTB;MUeuOFIyQSEQvF2=NFSxdpVUSU6JRWK=
MHH-NB-11NGHkN41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEGwNYJKSzVyPUG3Mlk3QDNizszNNXy5fI1CW0GQR1XS
MFM-223MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV;JR|UxRTF6LkC1N|gh|ryPMVPTRW5ITVJ?
ES7MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXfuc2RGUUN3ME2xPE42PDNzIN88US=>M3nwbXNCVkeHUh?=
JVM-3M3W1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTF6LkexO{DPxE1?MULTRW5ITVJ?
RLNWnidIM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTJyLkO4PEDPxE1?NFfFeVJUSU6JRWK=
EC-GI-10MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlfJTWM2OD1{MT6yNFQyKM7:TR?=M4fNN3NCVkeHUh?=
LNCaP-Clone-FGCNG\KbZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWjES3ZzUUN3ME2yNU43PzZ6IN88US=>M2TtenNCVkeHUh?=
IMR-5M2X3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nrOWlEPTB;MkGuPFQ6PCEQvF2=NEDkN21USU6JRWK=
KP-N-YSMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3y1W2lEPTB;MkGuPFc2KM7:TR?=MmHqV2FPT0WU
Mo-TNFTDbnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFL3ZVVKSzVyPUKyMlIyQDVizszNNXPyZ3VuW0GQR1XS
NCI-H128NXywRlUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFzsdW5KSzVyPUKzMlU5PTNizszNMXHTRW5ITVJ?
RH-1NVnLUphIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{nldGlEPTB;MkOuO|g3PiEQvF2=NEPSOGlUSU6JRWK=
NCI-H2171MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI\1O2ZKSzVyPUK0MlI1QDVizszNM4LIRXNCVkeHUh?=
RPMI-8866MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIj5V|NKSzVyPUK2Mlc1OiEQvF2=NXnBSmM2W0GQR1XS
SK-N-FIM33neGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTJ5LkO4NVEh|ryPM1\wcnNCVkeHUh?=
LOXIMVIMnX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\MNGlEPTB;MkeuPFA2OSEQvF2=MXPTRW5ITVJ?
P31-FUJMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTNzLkWzO|Qh|ryPMl7kV2FPT0WU
KMS-12-PENIXQXFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHtUVNZUUN3ME20PU42OzB{IN88US=>Mli4V2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Immunoblotting for the mTOR kinase assay HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr

Cell Assay:

[3]

Cell lines U87-MG, T98G, and U373-MG
Concentrations Dissolved in DMSO, final concentrations ~25 μM
Incubation Time 72 hours
Method

Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

Animal Study:

[7]

Animal Models Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
Formulation Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
Dosages ~4 mg/kg/day
Administration Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Edwards SR, et al. J Biol Chem, 2007, 282(18), 13395-13401.

[2] Barbet NC, et al. Mol Biol Cell, 1996, 7(1), 25-42.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-23)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02240407 Not yet recruiting Pompe Disease University of Florida October 2016 Phase 1
NCT02793544 Not yet recruiting Myelodysplastic Syndrome (MDS)|Chronic Lymphocytic Leukemia (CLL)|Chemotherapy-sensitive Lymphoma|Acute Lymphoblastic Leukemia (ALL)/T Lymphoblasti  ...more Myelodysplastic Syndrome (MDS)|Chronic Lymphocytic Leukemia (CLL)|Chemotherapy-sensitive Lymphoma|Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma|Acute Myelogenous Leukemia (AML)|Acute Biphenotypic Leukemia (ABL)|Acute Undifferentiated Leukemia (AUL) Center for International Blood and Marrow Transplant Rese  ...more Center for International Blood and Marrow Transplant Research|National Marrow Donor Program|Resource for Clinical Investigation in Blood and Marrow Transplantation August 2016 Phase 2
NCT02806947 Not yet recruiting Acute GVHD Medical College of Wisconsin|National Heart, Lung, and Bl  ...more Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|Blood and Marrow Transplant Clinical Trials Network|National Marrow Donor Program July 2016 Phase 2
NCT02642094 Not yet recruiting Cancer of Breast The University of Texas Health Science Center at San Antonio July 2016 Phase 0
NCT02768116 Not yet recruiting Coronary Heart Disease Beijing Anzhen Hospital June 2016 --

view more

Chemical Information

Download Rapamycin (Sirolimus) SDF
Molecular Weight (MW) 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms AY 22989,NSC-2260804
Solubility (25°C) * In vitro DMSO 20 mg/mL (21.87 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 0.5% CMC+0.25% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

Customer Product Validation(12)


Click to enlarge
Rating
Source Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines Persister cells
Concentrations 10 nM
Incubation Time 3 days
Results While added with a specific mTOR inhibitor, rapamycin(Rapa), it inhibitied endogenous mTOR activity, showed that markedly reduced MYC protein levels in persister cells but not in naive T-ALL cells.

Click to enlarge
Rating
Source Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck
Method Cell viability Analysis
Cell Lines Ar+murine (CaP8) and human (LNCaP) prostate cancer cells, Pb-Cre+;PtenL/L mice, Pb-Cre+;PtenL/L;ArL/Y mice
Concentrations 1 nM, 4 mg/kg
Incubation Time 0-4 weeks
Results These data suggest that CaPs with AR loss have greater reliance upon the PI3K/AKT/mTOR-signaling pathways and that combined AR/androgen blockage in conjunction with PI3K/AKT/mTOR inhibition (by Rapamycin) is more effective for CaPs initiated by PTEN loss or PI3K/AKT activation.

Click to enlarge
Rating
Source Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck
Method EdU labeling
Cell Lines MCF-7 cells
Concentrations 150 nM
Incubation Time 48 h
Results The punctate structures from SRC-3 or MIF knockdown cells are very similar to that found in cells treated with rapamycin, a known inducer of autophagy.

Click to enlarge
Rating
Source Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck
Method Cell imaging
Cell Lines H4-LC3-GFP cells
Concentrations 200 nM
Incubation Time 24 h
Results Consistent with inhibition of autophagy, the levels of LC3-II were lower and the levels of SQSTM1/p62 were higher in this USP18 knockdown cell line compared to that of control under basal conditions as well as the induced condition after the treatment with rapamycin.

Click to enlarge
Rating
Source Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck
Method Western blotting
Cell Lines HEK293 cells
Concentrations 250 nM
Incubation Time 24 h
Results Rapamycin virtually abolishes stimulation by Rheb of phospho-S6 kinase and phospho-4EBP1 but has negligible effects on phospho-eIF2a (A). In contrast to phosphorylation of eIF2a, which is not mediated by mTORC1, phosphorylation of other elongation factors does involve mTORC1. Thus, rapamycin prevents phosphorylation of eIF4G and eIF4B, targets of S6K, but not eIF2a (B). By contrast, rapamycin, as expected, abolishes phospho-S6 kinase but fails to influence phospho-eIF2a, phospho-Erk or phospho-Akt (C).

Click to enlarge
Rating
Source Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck
Method Immunofluorescence
Cell Lines RAW264.7 cells
Concentrations 10 uM
Incubation Time 16 h
Results It has been reported that autophagy can directly regulate inflammatory responses. To confirm this phenomenon, we pre-treated RAW264.7 cells with 3-MA (an autophagy inhibitor by blocking the class III PI3Ks) or rapamycin (an autophagy inducer by targeting the negative regulators against autophagy as mammalian target of rapamycin (mTOR)), followed by addition of LPS. LPS-induced punctate LC3 was markedly reduced and enhanced in the presence of 3-MA and rapamycin, respectively.

Click to enlarge
Rating
Source Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines H1299 cells
Concentrations 2 μM
Incubation Time 48 h
Results RAD001 and other mTOR inhibitors decreased the levels of survivin protein, as assessed by Western blot analysis, without affecting the levels of other IAP members. In addition, combined treatment with sorafenib and mTOR inhibitor Rapamycin and RAD001 decreased survivin expression to a greater extent than treatment with either alone.

Click to enlarge
Rating
Source J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck
Method Histological analysis, immunohistochemistry, Liver triglyceride content analysis, real-time PCR
Cell Lines Male SD rats
Concentrations
Incubation Time 7 d
Results To determine the effect of rapamycin, an mTOR inhibitor, in the OA-induced fatty liver, rats were fed 1% OA and administered rapamycin for seven days. OA-induced lipid accumulation was completely inhibited by the treatment with rapamycin (Fig. A). HE and Oil Red O staining of liver sections clearly confi rmed the results (Fig. B). Immunohistochemistry analyses showed signifi cantly repressed SREBP-1 in the rapamycin-cotreatment liver ( Fig. B ). All the downstream effectors of SREBP-1, such as Lxr-α, Acc, Scd-1 and Fas, were consistently suppressed by rapamycin ( Fig. C ).

Click to enlarge
Rating
Source Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck
Method Measurement of cytosolic free Ca2+concentration ([Ca2+]c )
Cell Lines Human platelets
Concentrations 500 nM
Incubation Time 30 min
Results Rapamycin administration significantly reduced TG-evoked Ca2+ -entry by 19. 5 ?9.4 %.

Click to enlarge
Rating
Source Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck
Method Microscope imaging
Cell Lines NCI-H1299 cells
Concentrations 10 uM
Incubation Time 48 h
Results Growth inhibition induced by rapamycin or erlotinib is enhanced by combination treatment with monensin in NCI-H1299 cells.

Click to enlarge
Rating
Source 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck
Method Western Blot
Cell Lines HeLa cells
Concentrations 0/2/20/200 nM
Incubation Time 24 h
Results

Click to enlarge
Rating
Source 2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines
Concentrations
Incubation Time 0-6 h
Results Rapamycin inhibits growth-dependent TCTP induction.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related mTOR Products

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively.

  • Dorsomorphin

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.

  • Everolimus (RAD001)

    Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.

  • AZD8055

    AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.

  • INK 128 (MLN0128)

    INK 128 (MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.

  • Tacrolimus (FK506)

    Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.

  • KU-0063794

    KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Recently Viewed Items

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) ic50 | Rapamycin (Sirolimus) price | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) solubility dmso | Rapamycin (Sirolimus) purchase | Rapamycin (Sirolimus) manufacturer | Rapamycin (Sirolimus) research buy | Rapamycin (Sirolimus) order | Rapamycin (Sirolimus) mouse | Rapamycin (Sirolimus) chemical structure | Rapamycin (Sirolimus) mw | Rapamycin (Sirolimus) molecular weight | Rapamycin (Sirolimus) datasheet | Rapamycin (Sirolimus) supplier | Rapamycin (Sirolimus) in vitro | Rapamycin (Sirolimus) cell line | Rapamycin (Sirolimus) concentration | Rapamycin (Sirolimus) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us